high efficacy DMTs
-
anti-CD20 therapy, Brain, cladribine, Delphi consensus, disease modifying therapy, high efficacy DMTs, multiple sclerosis, Neurodegenerative Diseases, neurology, neuroscience, patient involvement, personalized therapy, treatment adherenceMultiple Sclerosis Personalized Therapy: 70% Delphi Consensus
An Italian multiple sclerosis Delphi panel reached consensus on 116 of 166…
